CORESMA

To address the SARS-CoV-2 epidemic, timely clinical and epidemiologic data must be gathered

As part of this project, the NMI will use differential serolomics to assess seroprevalence, cross-immunity, and pre-existing immunity to coronaviruses.

Partner:

Period:
01.04.2020 - 31.03.2023
FKZ:
101003480
Funding:
HORIZON 2020

Projectlead

Dr. Nicole Schneiderhan-Marra

Head of Pharma & Biotech

+49 7121 51530-815
Contact via email
Show CV

NMI Natural and Medical Sciences Institute
at the University of Tübingen
Markwiesenstraße 55, 72770 Reutlingen
Tel.: +49 7121 51530-0
Mail: info@nmi.de

Follow us now

Subsidiary company
Member of
Member of